|
|
| RAC December 4, 2002 - Presentation Materials |
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
An Adverse Event in a Gene Transfer Clinical Trial for X-Linked Severe Combined Immunodeficiency Disease (SCID) |
|
|
| |
Theodore Friedmann, M.D., RAC Chair |
|
|
| |
Slides
|
|
| |
|
|
|
Review of FDA Biological Response Modifiers Advisory Committee Meeting |
|
|
| |
Stephanie L. Simek, Ph.D., U.S. Food and Drug Administration |
|
|
| |
Slides
|
|
| |
|
|
|
Review of October 29, 2002, RAC Planning Session |
|
|
| |
Stephen Rose, Ph.D., and/or Theodore Friedmann, M.D. |
|
|
| |
Slides
|
|
| |
|
|
|
Adverse Events in Clinical Trials Using Retroviral Vectors |
|
|
| |
Alexander Rakowsky, M.D., Office of Biotechnology Activities, NIH |
|
|
| |
Slides
|
|
| |
|
|
|
Monitoring Research Participants in Clinical Trials Using Retroviral Vectors |
|
|
| |
Theodore Friedmann, M.D., and Diane Wara, M.D., Moderator |
|
|
| |
Slides
|
|
| |
|
|
|
Monitoring for Insertional Oncogenesis and Clonality of Hemotopoiesis after Gene Therapy |
|
|
| |
Slides
|
|
| |
|
|
|
ADJOURN |
|
| |
|
Top of Page |
| |
|
|
|
|
